clonidine has been researched along with Adverse Drug Event in 18 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17." | 5.13 | Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. ( Bukstein, OG; Daviss, WB; Harris, P; McDERMOTT, MP; Palumbo, D; Patel, NC; Pelham, WE; Robb, AS; Sallee, FR, 2008) |
| " The dosage of the clonidine adhesive patch was 1." | 2.73 | Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. ( Du, YS; Jiao, FY; Li, HF; Ma, SW; Su, LY; Vance, A; Wang, HM; Wang, MJ; Wu, JB; Yu, DL; Zhong, YQ, 2008) |
| " Withdrawals due to all-cause, adverse effects and lack of efficacy were defined as primary outcomes evaluating the safety of such medications." | 2.55 | An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. ( Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y, 2017) |
| "Tizanidine is an alpha2 agonist with central action whose myorelaxant effects are often used off-label against primary backpain in clinical practice." | 1.62 | [Focus on tizanidine in primary care medecine]. ( Frascarolo, S; Moutinot, B; Sartori, C, 2021) |
| " The existing side effect prediction methods mainly focus on the chemical and biological properties of drugs." | 1.56 | Prediction of Side Effects Using Comprehensive Similarity Measures. ( Kim, MH; Lee, T; Seo, S; Yoon, Y, 2020) |
| "Potential drug-drug interactions (pDDIs) are described in various case reports, but few studies have evaluated the impact of specific combinations on a population level." | 1.48 | Analysis of Drug-Drug Interactions in Swiss Claims Data Using Tizanidine and Ciprofloxacin as a Prototypical Contraindicated Combination. ( Curkovic, I; Egbring, M; Jödicke, AM; Kullak-Ublick, GA; Neuer, T; Roos, M; Tomka, IT; Zellweger, U, 2018) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "Tizanidine is an imidazoline with central alpha(2)-adrenoceptor agonist activity at both spinal and supraspinal levels, which is indicated as a short-acting drug for the management of spasticity." | 1.35 | Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment. ( Chez, M; Henney, HR, 2009) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Seo, S | 1 |
| Lee, T | 1 |
| Kim, MH | 1 |
| Yoon, Y | 1 |
| Frascarolo, S | 1 |
| Moutinot, B | 1 |
| Sartori, C | 1 |
| Jödicke, AM | 1 |
| Curkovic, I | 1 |
| Zellweger, U | 1 |
| Tomka, IT | 1 |
| Neuer, T | 1 |
| Kullak-Ublick, GA | 1 |
| Roos, M | 1 |
| Egbring, M | 1 |
| Li, Y | 1 |
| Gao, J | 1 |
| He, S | 1 |
| Zhang, Y | 1 |
| Wang, Q | 1 |
| Du, YS | 1 |
| Li, HF | 1 |
| Vance, A | 1 |
| Zhong, YQ | 1 |
| Jiao, FY | 1 |
| Wang, HM | 1 |
| Wang, MJ | 1 |
| Su, LY | 1 |
| Yu, DL | 1 |
| Ma, SW | 1 |
| Wu, JB | 1 |
| Henney, HR | 1 |
| Chez, M | 1 |
| Jain, R | 1 |
| Segal, S | 1 |
| Kollins, SH | 1 |
| Khayrallah, M | 1 |
| Duong, S | 1 |
| Chung, K | 1 |
| Wigal, SB | 1 |
| Adeishvili-Anguladze, LV | 1 |
| Makharadze, RV | 1 |
| Kurtsikidze, MSh | 1 |
| Abuladze, NB | 1 |
| Kintsurashvili, KM | 1 |
| Daviss, WB | 1 |
| Patel, NC | 1 |
| Robb, AS | 1 |
| McDERMOTT, MP | 1 |
| Bukstein, OG | 1 |
| Pelham, WE | 1 |
| Palumbo, D | 1 |
| Harris, P | 1 |
| Sallee, FR | 1 |
| Clark, BG | 1 |
| Vestal, RE | 1 |
| Okonek, S | 1 |
| van Zwieten, PA | 1 |
| Lackner, TE | 1 |
| Feldstein, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Behavioral Therapy for Children and Adolescents With Tourette Syndrome: A Randomized Controlled Trial in Taiwan[NCT03621059] | 46 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)[NCT00556959] | Phase 3 | 236 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for clonidine and Adverse Drug Event
| Article | Year |
|---|---|
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidi | 2017 |
Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2012 |
3 trials available for clonidine and Adverse Drug Event
| Article | Year |
|---|---|
Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-Agonists; Child; China; Clonidine; Dose-Resp | 2008 |
Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Chi | 2011 |
Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Chi | 2011 |
Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Chi | 2011 |
Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Chi | 2011 |
Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Bradycardia; Central Nervo | 2008 |
13 other studies available for clonidine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Prediction of Side Effects Using Comprehensive Similarity Measures.
Topics: Area Under Curve; Clonidine; Dasatinib; Drug Interactions; Drug Repositioning; Drug-Related Side Eff | 2020 |
[Focus on tizanidine in primary care medecine].
Topics: Clonidine; Drug-Related Side Effects and Adverse Reactions; Humans; Primary Health Care | 2021 |
Analysis of Drug-Drug Interactions in Swiss Claims Data Using Tizanidine and Ciprofloxacin as a Prototypical Contraindicated Combination.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Clonidine; Cohort | 2018 |
Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 8 | 2009 |
[New methods of chemical and toxicological study of clonidine (Clophelinum)].
Topics: Antihypertensive Agents; Chromatography; Clonidine; Drug-Related Side Effects and Adverse Reactions; | 2007 |
Adverse drug reactions in the elderly: case studies.
Topics: Acetazolamide; Aged; Anemia, Hemolytic; Bromocriptine; Captopril; Chlorpropamide; Cimetidine; Clonid | 1984 |
[On the importance of clinical cases of intoxication as involuntary toxicological trials for clinical pharmacology (author's transl)].
Topics: Biguanides; Clonidine; Digoxin; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceuti | 1978 |
A survey of drug interaction.
Topics: Antacids; Clonidine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Indu | 1977 |
Your CE topic (No. 111). Clinical application of transdermal drug delivery systems (Part II).
Topics: Administration, Cutaneous; Clonidine; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; | 1990 |
Hypertensive emergencies.
Topics: Adrenal Gland Neoplasms; Angina Pectoris; Antihypertensive Agents; Aortic Aneurysm; Aortic Dissectio | 1986 |